logo

For the Inventor, By the Inventor

Wuppertal, Germany

Michael Lögers

This inventor holds 6 USPTO granted patents. Top assignee: Bayer Aktiengesellschaft. Active years: 2001-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Lögers. Retrieved from https://idiyas.com/inventor/michael-landoumlgers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 66.7

Average Co-Inventor Count = 9.6

ph-index = 5

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal6 out of 12,268 
 
Bayer Aktiengesellschaft
 patents

Years Active: 2001-2004

Loading Chart...
6 patents (USPTO):Explore Patents
1. 6699857 - Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives and use thereof (2004-03-02),
2. 6586613 - Substituted tetrahydronaphthaline and analogous compounds (2003-07-01),
3. 6562976 - 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein (2003-05-13),
4. 6387929 - 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein (2002-05-14),
5. 6291477 - Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia (2001-09-18),
6. 6207671 - Cycloalkano-pyridines (2001-03-27),

Title: The Innovative Contributions of Michael Lögers

Introduction

Michael Lögers is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative patents. With a total of 6 patents to his name, Lögers has focused on developing compounds that have the potential to treat various medical conditions.

Latest Patents

Among his latest patents are the "Tetrahydroquinolinyl 6-methyldihydrothiadiazinone derivatives" and "Substituted tetrahydronaphthaline and analogous compounds." These compounds are synthesized by reducing or condensing appropriate functional substituents in substituted tetrahydronaphthalenes. The resulting compounds are particularly suitable for use as active ingredients in pharmaceuticals aimed at treating arteriosclerosis and dyslipidaemias.

Career Highlights

Lögers has had a distinguished career, working with prominent companies such as Bayer Aktiengesellschaft. His work has contributed to advancements in pharmaceutical research and development, showcasing his expertise in the field.

Collaborations

Throughout his career, Michael Lögers has collaborated with esteemed colleagues, including Carsten Schmeck and Jürgen Stoltefuss. These collaborations have further enhanced his innovative capabilities and have led to the successful development of various pharmaceutical compounds.

Conclusion

Michael Lögers stands out as a significant figure in the realm of pharmaceutical innovation. His contributions through patents and collaborations have the potential to impact the treatment of critical health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…